… enrolled on clinical trials of agents to treat acquired resistance to erlotinib or gefitinib. …
mandated TKI discontinuation before administration of study therapy. Disease flare was defined as …

… Median PFS in 217 patients treated with erlotinib was 14 … the European Tarceva versus
Chemotherapy (EURTAC) study, … either erlotinib or gefitinib, dependent on the standard of care at …

… of the present study suggested that shikonin could promote erlotinib/gefitinib-induced apoptosis
… The dose of erlotinib/gefitinib selected in the present study was not expected to exhibit …

… the success rate of gefitinib, erlotinib and icotinib have been reported. In the current study, a
… effects of gefitinib, erlotinib and icotinib for the treatment of patients with advanced NSCLC. …

… therapy were instructed to interrupt gefitinib treatment during treatment. Patients who required
… of separate clinical studies of single agent gefitinib and erlotinib in patients with BAC. …

… t if frd 1i ne treat me nt of NSCLC e spec i al ly among never -… QoL) and pr ol onged t he s
urvi val ti me in pr evious studies … the study and all of th em we rea ss es s abl e f or r es pons e …

… Twenty-seven patients were enrolled in this study. The median number of … In conclusion,
we showed that combined pemetrexed and erlotinib or gefitinib therapy after the relapse to …

… However, results in the present study showed that combined γ-tocotrienol and erlotinib or
gefitinib treatment had no effect on the Src activation, and suggests that combined treatment-…

… beyond the first follow-up visit postprogression may have alleviated the issue of missing data;
however, this could have led to the occurrence of several potential challenges in this study: …

… However, several studies have documented the effectiveness … gefitinib treatment due to its
higher penetration rate to cerebrospinal fluid. For these reasons, we chose erlotinib treatment …